Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and